Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Slides:

Advertisements

Similar presentations

What Is Meant by "Real-World Data?"

Advertisements

Long-term Safety and Effectiveness of Natalizumab STRATA MS Study.

Efficacy of fidaxomicin vs vancomycin for C. difficile-associated diarrhoea (CDAD) in pts with cancer Post-hoc analysis of 2 multi-centre, double-blind.

FREEDOMS II TRIAL.

An Analysis of Monthly Surveillance 3T MRI in MS patients switched from long term natalizumab to teriflunomide in a controlled, prospective study K. Edwards,

Carrie M. Hersh, D.O., Robert Fox, M.D.

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

Multiple sclerosis: Oral Therapies and Beyond

Propensity Score Adjustment for Comparative Efficacy Studies of Disease Modifying Agents in Multiple Sclerosis Carrie M. Hersh, DO,1 Claire Hara-Cleaver,

Chronic Hepatitis C Virus Infection

MS Highlights From the 2017 Annual Neurology Meeting

Program Goals Teriflunomide: Pooled Safety Data.

HCV: Who Should We Screen and Why?

When Is Adding Aspirin to NOACs Worth the Risk?

Heart Rate, HF Admissions, and Readmissions

Immune Reconstitution in MS:

Current Controversies in Multiple Sclerosis Management

Modern Strategies for Basal Insulin Use in T2D

PAD Patients vs Post-ACS Patients:

Applying Real-World Evidence in MS: Reviewing the State of the Art

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Perspectives on Key MS Data From the Annual Neurology Meeting

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Managing Hereditary Angioedema

Statin Selection in Special Patient Populations: A Case Challenge

Before and After: Patient Cases in Onychomycosis

T-Cell Directed Therapy in MS

Current and Future Goals in the Treatment of Relapsed CLL

nAMD: Switching Therapies - what you need to know

Iron Deficiency Anemia

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Are We Closer to Personalized Medicine in MS?

New Agents, New Regimens, New Strategies

Should I Stay or Should I Go?

Navigating New Oral Treatment Algorithms in CLL

Program Goals Disclaimer Overview Assessing Disease Activity.

Managing Adverse Events With New Oral Therapies in CLL

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Charting Progress in MS Treatment:

Treating to Target in MS

Iron Deficiency Anemia

Introduction. Clinical Scenario: Encouraging Adherence in Patients with Schizophrenia.

Overview. Complex Cases in PCI: Tailoring Antiplatelet Therapy to Improve Outcomes.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Program Goals Overview Is NEDA a Reasonable Target?

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Factor Xa Inhibitors in PAD

CAD/PAD in Primary Care

Opportunistic Infections in MS What Is the Risk?

Clinical Pearls on Hot Topics in MS

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Pregnancy in MS.

Proteasome Inhibitors and Patients

Factor Xa Inhibitors in Coronary Artery Disease

Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.

5 Good Minutes on Atrial Fibrillation-related Stroke

Program Goals Overview Is NEDA a Reasonable Target?

Oral Therapies in MS.

Figure 5 Increased B cell-activating factor (BAFF) levels are shared between immunomodulatory treatments Increased B cell-activating factor (BAFF) levels.

Novel Therapeutics in MS

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Mitigating Infection Risk With DMT in MS

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

MS, Age, and Immune Function

Treatment Advances for RA

PCSK9 Inhibitors and Real-World Evidence

Understanding the Role of Disability in MS Management

Selective Immunomodulation in MS

What's New in NOACs in AF?.

Presentation transcript:

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

MSBase and TOP: Switch to Fingolimod or Natalizumab vs BRACE Therapies

PREFERMS: Patients Switching to Fingolimod From IFN-β or GA

Efficacy of DMF by Prior DMT Use

PML Risk/Year Stratified by Index Value

Fingolimod: Relapse Rates in Patients Who Discontinue Natalizumab

Risk for PML With MS Therapies

Shorter Natalizumab Washout Periods Are Associated With Less Disease Activity

The Impact of Switching Time From Natalizumab to Fingolimod on Imaging and Clinical Effectiveness Outcomes

Fingolimod 0.5 mg and Major Infections

Abbreviations

Abbreviations (cont)